Sagimet Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SGMT Nasdaq 8731 https://sagimet.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sagimet Biosciences Inc

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 - Apr 22nd, 2024 12:00 pm
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat - Mar 27th, 2024 8:01 pm
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - Mar 25th, 2024 11:00 am
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates - Mar 25th, 2024 10:15 am
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - Feb 29th, 2024 1:00 pm
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock - Jan 26th, 2024 1:58 am
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock - Jan 23rd, 2024 10:45 pm
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH - Jan 22nd, 2024 12:00 pm
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic - Dec 4th, 2023 1:00 pm
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit - Nov 28th, 2023 1:00 pm
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference - Nov 22nd, 2023 1:00 pm
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates - Nov 13th, 2023 1:00 pm
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023 - Nov 10th, 2023 1:30 pm
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023 - Oct 24th, 2023 3:00 pm
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference - Oct 18th, 2023 8:05 pm
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma - Sep 27th, 2023 8:05 pm
‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks - Aug 29th, 2023 2:21 pm
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates - Aug 21st, 2023 8:02 pm
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering - Aug 15th, 2023 8:04 pm
Sagimet Biosciences Announces Leadership Changes - Jul 20th, 2023 8:05 pm